US drugmaker Bristol-Myers Squibb and Swiss fine and specialty chemicals specialist Lonza have announced a multi-year expansion of their existing biologics manufacturing agreement.
The contract extension will include the production of commercial quantities of a second Bristol-Myers Squibb biologic medicine at Lonza's mammalian manufacturing facility in Portsmouth, New Hampshire, in the US.
Effective August 1, 2014, Dieter Weinand will become president of Bayer HealthCare Pharmaceuticals and at the same time join the Executive Committee of Bayer HealthCare. He replaces Andreas Fibig, who will leave Bayer on September 1, 2014, to become CEO of International Flavours and Fragrances.
Danish drugmaker Novo Nordisk, the world's biggest insulin producer, has decided to launch its diabetes drug Tresiba in Germany after seeing signs of a more favorable pricing situation there.
Tresiba was approved in the European Union last year, but despite Germany being Europe's biggest market Novo hesitated to market the drug there because German authorities have been reluctant to support new and more expensive treatments.
DKSH Business Unit Healthcare has extended the relationship started in 2010 with Bristol-Myers Squibb, covering six markets in Asia (Hong Kong, Malaysia, Singapore, Taiwan, Thailand and Vietnam).
The Supervisory Board of Bayer AG appointed Kemal Malik (51) to the Board of Management of Bayer AG effective February 1, 2014. Malik has been a member of the Bayer HealthCare Executive Committee, Head of Global Development and Chief Medical Officer since July 1, 2007.
German healthcare company Merck expects to get a long-term boost from study results in June that showed its main cancer drug Erbitux has an edge over rival product Avastin.
Erbitux, which accounted for roughly 8 % of Merck's €10.7 billion in sales last year, in June was shown to be more effective at prolonging the lives of colorectal cancer patients than Roche's Avastin.
Roche will halt development of a diabetes drug partly because of its undesired side-effects, marking another high-profile setback for the Swiss company as it struggles to diversify outside its core cancer drug portfolio.
The news is a fresh blow for Roche's Basel research operations, known as pRED, which have languished in the shadow of the work done at Genentech, the 2009 acquisition that cooked up Roche's four top-selling medicines in 2011.
Turning around drugmaker AstraZeneca will be a long haul, with a strategy of revamping research and boosting acquisitions set to take up to four years to pay off, its chief executive said on Tuesday.
A former Bristol-Myers Squibb finance executive on Monday pleaded guilty to an insider trading charge, admitting to buying stock options in a biotechnology company that the drugmaker was preparing to buy.
Robert Ramnarine, 46, admitted to one count of securities fraud for trading in Amylin Pharmaceuticals options before Bristol-Myers agreed to buy that company last June for $5.3 billion, U.S. Attorney Paul Fishman in New Jersey said.
In a leafy suburb of Frankfurt, a state-of-the-art plant churns out up to 1 million insulin pens every day in French drugmaker Sanofi's drive to keep its no. 2 spot in the $43 billion-a-year diabetes market.
The facility is part of a hub - nicknamed Insulin City - dedicated to research and development, production, and smart technology for diabetes treatments that Sanofi says will help drive its growth as older blockbusters lose patent protection.